Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2020-12-14
Target enrollment:
Participant gender:
Summary
A Phase 2 study to investigate the antitumor activity in terms of overall response rate (ORR)
of tipifarnib in approximately 36 eligible subjects with Myelodysplastic/Myeloproliferative
Neoplasias (MDS/MPN), including Chronic Myelomonocytic Leukemia (CMML), and 36 eligible
subjects with Acute Myeloid Leukemia (AML). Subjects (amendment 3 Cohorts 1-4) will receive
tipifarnib administered at a dose of 400 mg, orally with food, twice a day (bid) for 21 days
in 28 day cycles.